Novartis to trial canakinumab to treat Covid-19 pneumonia
Canakinumab is the third drug candidate to be studied by the company for Covid-19 treatment. Credit: Novartis AG.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more